pubmed-article:15703816 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0086418 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0376358 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0026336 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0027627 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0021467 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0598934 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C2677316 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0021469 | lld:lifeskim |
pubmed-article:15703816 | lifeskim:mentions | umls-concept:C0950779 | lld:lifeskim |
pubmed-article:15703816 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:15703816 | pubmed:dateCreated | 2005-2-10 | lld:pubmed |
pubmed-article:15703816 | pubmed:abstractText | TNP-470, a potent inhibitor of angiogenesis, was reported to synergistically enhance the antitumor effects of cytotoxic agents. The objective of this study was to evaluate the effectiveness of combined treatment with TNP-470 and docetaxel both in vitro and in vivo using androgen-independent human prostate cancer PC-3 cells. The in vitro growth-inhibitory and apoptotic effects of docetaxel and/or TNP-470 on PC-3 cells were assessed using MTT and TUNEL assays. The combined effect of docetaxel and TNP-470 therapy after subcutaneous and orthotopic injection of PC-3 cells into athymic nude mice was evaluated. In vivo effects of this combined regimen on PC-3 tumors were analyzed by the TUNEL assay and immunohistochemical staining of CD31 to quantify microvessel density (MVD). Combined treatment with TNP-470 and docetaxel synergistically inhibited PC-3 cell growth in vitro through the enhanced induction of apoptotic cell death compared with treatment with either agent alone, a result explained, at least in part, by the down-regulation as well as phosphorylation of potential anti-apoptotic genes, Bcl-2 and Bcl-XL. Combined treatment with TNP-470 and docetaxel synergistically suppressed subcutaneous PC-3 tumor growth compared with treatment with either agent alone. Furthermore, this combined regimen significantly inhibited orthotopic PC-3 tumor growth and reduced the incidence of lymph node metastasis. Immunohistochemical analysis of the subcutaneous tumor after each treatment demonstrated that administration of docetaxel as well as TNP-470 significantly induced apoptotic cell death; in contrast, a significant reduction in MVD was observed only after TNP-470. These findings suggest that docetaxel and TNP-470 act synergistically to inhibit PC-3 tumor growth and metastasis, by enhancing apoptosis and suppressing angiogenesis. | lld:pubmed |
pubmed-article:15703816 | pubmed:language | eng | lld:pubmed |
pubmed-article:15703816 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:15703816 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:15703816 | pubmed:month | Mar | lld:pubmed |
pubmed-article:15703816 | pubmed:issn | 1019-6439 | lld:pubmed |
pubmed-article:15703816 | pubmed:author | pubmed-author:KamidonoSadao... | lld:pubmed |
pubmed-article:15703816 | pubmed:author | pubmed-author:MiyakeHideaki... | lld:pubmed |
pubmed-article:15703816 | pubmed:author | pubmed-author:HaraIsaoI | lld:pubmed |
pubmed-article:15703816 | pubmed:author | pubmed-author:MuramakiMotot... | lld:pubmed |
pubmed-article:15703816 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:15703816 | pubmed:volume | 26 | lld:pubmed |
pubmed-article:15703816 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:15703816 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:15703816 | pubmed:pagination | 623-8 | lld:pubmed |
pubmed-article:15703816 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:meshHeading | pubmed-meshheading:15703816... | lld:pubmed |
pubmed-article:15703816 | pubmed:year | 2005 | lld:pubmed |
pubmed-article:15703816 | pubmed:articleTitle | Synergistic inhibition of tumor growth and metastasis by combined treatment with TNP-470 and docetaxel in a human prostate cancer PC-3 model. | lld:pubmed |
pubmed-article:15703816 | pubmed:affiliation | The Prostate Centre, Jack Bell Research Centre, Vancouver, British Columbia V6H 3Z6, Canada. mmuramak@vanhosp.bc.ca | lld:pubmed |
pubmed-article:15703816 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15703816 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15703816 | lld:pubmed |